adamantane has been researched along with rifampin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P; Einck, L; Gearhart, J; Nacy, CA; Protopopova, M | 1 |
| Coutinho, E; Jain, R; Malde, A; Monga, V; Nayyar, A | 1 |
| Zhang, Y | 1 |
| Andries, K; Einck, L; Nacy, CA; Reddy, VM | 1 |
| Boulton, DW; Ching, A; Lacreta, FP; Li, L; Patel, CG; Su, H; Upreti, VV | 1 |
| Averell, N; Overstreet, D; Thatiparti, TR; von Recum, HA | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Aarnoutse, RE; Boeree, MJ; Dawson, R; Diacon, AH; du Bois, J; Gillespie, SH; Heinrich, N; Henne, S; Hoelscher, M; Horwith, G; Nacy, CA; Narunsky, K; Phillips, PP; Phipps, AJ; Rachow, A; Venter, A | 1 |
| Diacon, AH; Donald, PR; Friedrich, SO; Kayigire, XA; van der Merwe, L | 1 |
| Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS | 1 |
| Cole, ST; Foscolos, AS; Foscolos, GB; Kolocouris, N; Papanastasiou, I; Tsotinis, A; Vocat, A | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
| Ke, M; Lin, C; Lin, R; Wu, W; Ye, L | 1 |
2 review(s) available for adamantane and rifampin
| Article | Year |
|---|---|
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
3 trial(s) available for adamantane and rifampin
| Article | Year |
|---|---|
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethylenediamines; Female; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2015 |
Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.
Topics: Adamantane; Antitubercular Agents; Bacterial Load; Benzophenoneidum; Colony Count, Microbial; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Fluorescent Dyes; Humans; Lipid Droplets; Microscopy, Fluorescence; Mycobacterium tuberculosis; Oxazines; Predictive Value of Tests; Rifampin; South Africa; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2015 |
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary | 2017 |
8 other study(ies) available for adamantane and rifampin
| Article | Year |
|---|---|
Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
Topics: Adamantane; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Ethylenediamines; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Rifampin | 2006 |
Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.
Topics: Adamantane; Antitubercular Agents; Chromatography, Thin Layer; Computer Simulation; Isoniazid; Least-Squares Analysis; Ligands; Magnetic Resonance Spectroscopy; Mass Spectrometry; Microbial Sensitivity Tests; Models, Molecular; Mycobacterium tuberculosis; Quantitative Structure-Activity Relationship; Quinolines; Rifampin; Spectrometry, Mass, Electrospray Ionization | 2007 |
In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Interactions; Ethylenediamines; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolines; Rifampin | 2010 |
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.
Topics: Adamantane; Adolescent; Adult; Antibiotics, Antitubercular; Area Under Curve; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Rifampin; Young Adult | 2011 |
Multiplexing interactions to control antibiotic release from cyclodextrin hydrogels.
Topics: Adamantane; Aminocoumarins; Binding Sites; Cyclodextrins; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Compounding; Humans; Hydrogels; Kinetics; Novobiocin; Polyethylene Glycols; Rifampin; Solutions; Spectroscopy, Fourier Transform Infrared; Staphylococcus epidermidis | 2011 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
Synthesis of Adamantane Aminoethers with Antitubercular Potential.
Topics: Adamantane; Amines; Antitubercular Agents; Ethambutol; Models, Chemical; Molecular Structure; Mycobacterium tuberculosis; Rifampin | 2017 |
Physiologically Based Pharmacokinetic Modeling Characterizes the Drug-Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment.
Topics: Adamantane; Adult; Cytochrome P-450 CYP3A; Dipeptides; Drug Interactions; Humans; Models, Biological; Rifampin | 2023 |